ENCePP Stakeholders

Interested parties and stakeholders of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) include:

• Clinical and pharmacoepidemiological research organisations
• National and regional pharmacovigilance centres
• Regulatory authorities - e.g. European Commission, European Medicines Agency, National Competent Authorities (NCAs)
• Patients and patients' organisations
• Health care professionals (pharmacists and medical practitioners) and their professional organisations
• Academia and learned societies in the EU
• Pharmaceutical and medical devices industry (marketing authorisation holders/Applicants)
• Public and public/private funding bodies (e.g. Innovative Medicines Initiative (IMI) and European Commission's DG Research)

Prior to the launch of the ENCePP project, the European Medicines Agency held meetings with a number of representatives of the identified stakeholders. The following parties were consulted:

- HMA, Heads of Medicines Agencies
- CHMP, Committee for Medicinal Products for Human Use
- PhVWP-CHMP, Pharmacovigilance Working Party
- ISPE, International Society for Pharmacoepidemiology
- ISoP, International Society of Pharmacovigilance
- EACPT, European Association for Clinical Pharmacology and Therapeutics
- ISPOR, International Society for Pharmacoeconomics and Outcomes Research
- PCWP-CHMP, Working Party with Patients' and Consumers' Organisations
- HCP WG, (Health Care Professionals Working Group)
- Pharmaceutical industry (AstraZeneca, Novartis, GSK, Pfizer, EliLilly and EFPIA)
- DG Research - European Commission's Directorate-General for Research
- Pan-EU and international organisations, e.g.UK Clinical Research Network (UKCRN), European Group for Blood and Marrow Transplantation (EBMT), European Surveillance Network of Psoriasis (PSONET), European Registry of Severe Cutaneous Adverse Reactions (RegiSCAR)